Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets | Zendy

Khandave Suhas | Zendy; Satish V Sawant | Zendy; Santosh Joshi | Zendy; Yatish Bansal | Zendy; Sonal Sushil Kadam | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Comparative bioequivalence studies of tramadol hydrochloride sustained-release 200 mg tablets

Author(s) -

Khandave Suhas,

Satish V Sawant,

Santosh Joshi,

Yatish Bansal,

Sonal Sushil Kadam

Publication year - 2010

Publication title -

drug design development and therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.964

H-Index - 64

ISSN - 1177-8881

DOI - 10.2147/dddt.s15133

Subject(s) - bioequivalence , tramadol , pharmacokinetics , crossover study , tramadol hydrochloride , medicine , pharmacology , bioavailability , metabolite , half life , dosing , cyp2d6 , confidence interval , analgesic , chromatography , chemistry , alternative medicine , pathology , cytochrome p450 , metabolism , placebo

Tramadol hydrochloride is available as 50 mg immediate-release (IR) and 100 mg, 200 mg, and 300 mg sustained-release (SR) tablets. The recommended dose of tramadol is 50-100 mg IR tablets every 4-6 hours. The tramadol SR 200 mg tablet is a better therapeutic option, with a reduced frequency of dosing, and improved patient compliance and quality of life. The present study evaluated the bioequivalence of a generic tramadol SR 200 mg tablet.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research